Biote (BTMD) Accounts Receivable : $8.0 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Biote Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Biote's accounts receivables for the quarter that ended in Mar. 2024 was $8.0 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Biote's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 15.64.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Biote's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-2.97.

Biote Accounts Receivable Historical Data

The historical data trend for Biote's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biote Accounts Receivable Chart

Biote Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

4.72

5.23

6.95

6.81

Biote Quarterly Data
	Dec19	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial									7.65	8.34	10.18	6.81	8.02

Biote Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Biote Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Biote's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	8.022	/	46.804	*	91
=	15.64

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Biote's accounts receivable are only considered to be worth 75% of book value:

Biote's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(78.787	+	0.75 * 8.022	+	0.5 * 18.917	-	205.008
-	0	-	-9.501)	/	34.0642
=	-2.97

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Biote Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Biote's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Biote (BTMD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Biote Corp (NAS:BTMD) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

1875 West Walnut Hill Lane, Suite 100, Irving, TX, USA, 75038

Website

https://www.biote.com

Biote Corp is engaged in bioidentical hormone replacement optimization platform and complementary nutraceutical business. The company offers end-to-end platform that provides practitioners with medical education, training and certification, practice management software, and digital and point-of-care marketing support.

Executives

Mary Elizabeth Conlon	officer: General Counsel	C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038
Anil K Shrivastava	10 percent owner	200 PARK AVENUE, 17TH FLOOR, NEW YORK NY 10016
Michael David Braner	10 percent owner	200 PARK AVENUE, 17TH FLOOR, NEW YORK NY 10016
Daniel M. Friedberg	10 percent owner	C/O SAGARD CAPITAL, 325 GREENWICH AVENUE, GREENWICH CT 06830
325 Capital Llc	10 percent owner	757 THIRD AVENUE, 20TH FLOOR, NEW YORK NY 10017
Mary Joan Puncochar	officer: Chief Commercial Officer	C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038
Roystone Capital Holdings Llc	10 percent owner	767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Roystone Capital Management Lp	10 percent owner	780 THIRD AVENUE, 41ST FLOOR, NEW YORK NY 10017
Samar Jagat Kamdar	officer: Chief Financial Officer	7042 CORONADO AVE., DALLAS TX 75214
Marc D Beer	director	C/O AEGERION PHARMACEUTICALS, 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960
Guines Llc	10 percent owner	767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Richard R Barrera	10 percent owner	767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Debra L Morris	director	11620 WILSHIRE BOULEVARD, SUITE 1000, LOS ANGELES CA 90025
Andrew R Heyer	director, officer: President and Director	501 MADISON AVENUE, FLOOR 5, NEW YORK NY 10019
Teresa Sue Weber	director, officer: Chief Executive Officer	C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038